Avalon GloboCare Announces Filing of Provisional Patent Applications for AVA-101, a Novel Transposon-Based, Multi-Targeted CA...
February 26 2019 - 8:00AM
AVA-101 designed to enhance efficacy and
overcome safety challenges of current CAR-T immune-oncology
therapeutics
Avalon GloboCare Corp. (NASDAQ: AVCO) (NASDAQ listed Avalon
GloboCare AVCO), a leading global developer of innovative and
transformative cell-based technologies and therapeutics, announced
today that the Company and Arbele Limited (joint venture partner)
have jointly filed provisional patent applications covering method
and composition of matter claims for AVA-101, a novel
multi-targeted, transposon-based Chimeric Antigen Receptor (CAR)-T
cellular immunotherapy. These unique CAR vector constructs
are non-virally engineered, possessing multiple therapeutic targets
as well as unique “safety-switch" control mechanisms, designed to
provide more effective therapy and overcome toxicities of current
CAR-T therapy.
This set of patent applications primarily involves an
innovative, versatile and inducible transposon-based vector system
composed of humanized CD19 and CD22 dual and bispecific CARs with a
safety switch targeted by Rituximab. Furthermore, the system
enables a combination therapy with anti-immune check point
inhibitors as well as other factors to support effector CAR-T cell
survival for more efficacious, durable and safer cellular
immunotherapy for treating patients with progressive hematologic
malignancies.
“We are very excited to achieve this milestone after
establishing our joint venture with Arbele Limited on January 3,
2019,” stated David Jin, M.D., Ph.D., CEO and President of Avalon
GloboCare Corp. “This patent application, together with
Avalon’s extensive hospital network for cellular therapy and our
established GMP bio-production facility in China, should allow
Avalon to accelerate the clinical development of better and safer
CAR-T therapies and, as a result, further establish our leadership
in the field of immuno-oncology and cell-based therapeutics,” added
Dr. Jin.
About Avalon GloboCare Corp.
Avalon GloboCare Corp. (NASDAQ: AVCO) is a global intelligent
biotech developer and healthcare service provider dedicated to
advancing cell-based technologies and therapeutics, with a focus on
developing and empowering innovative and transformative cell-based
technologies and their clinical applications. In addition,
Avalon provides strategic advisory and outsourcing services to
facilitate and enhance its clients' growth, development, as well as
competitiveness in both the domestic and global healthcare
markets. Through its subsidiaries, namely GenExosome
Technologies Inc. and Avactis Biosciences Inc., Avalon is
establishing a leading role in the fields of exosome-based
diagnostics, cellular immunotherapy (including CAR-T/CAR-NK), and
regenerative medicine.
Forward-Looking Statements
Certain statements contained in this press
release may constitute "forward-looking
statements." Forward-looking statements provide current
expectations of future events based on certain assumptions and
include any statement that does not directly relate to any
historical or current fact. Actual results may differ materially
from those indicated by such forward-looking statements as a result
of various important factors as disclosed in our filings with the
Securities and Exchange Commission located at their website
(http://www.sec.gov). In addition to these factors, actual future
performance, outcomes, and results may differ materially because of
more general factors including (without limitation) general
industry and market conditions and growth rates, economic
conditions, and governmental and public policy changes. The
forward-looking statements included in this press release represent
the Company's views as of the date of this press release and these
views could change. However, while the Company may elect to update
these forward-looking statements at some point in the future, the
Company specifically disclaims any obligation to do so. These
forward-looking statements should not be relied upon as
representing the Company's views as of any date subsequent to the
date of the press release.
Contact Information: Avalon GloboCare
Corp. 4400 Route 9, Suite 3100 Freehold, NJ 07728
PR@Avalon-GloboCare.com
Investor Relations: Crescendo Communications,
LLC Tel: (212) 671-1020 avco@crescendo-ir.com
Avalon GloboCare (NASDAQ:AVCO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Avalon GloboCare (NASDAQ:AVCO)
Historical Stock Chart
From Apr 2023 to Apr 2024